124 related articles for article (PubMed ID: 6819013)
1. Pharmacokinetics of valproic acid and metabolites in mouse plasma and brain following constant-rate application of the drug and its unsaturated metabolite with an osmotic delivery system.
Nau H; Zierer R
Biopharm Drug Dispos; 1982; 3(4):317-28. PubMed ID: 6819013
[TBL] [Abstract][Full Text] [Related]
2. Comparative transfer of valproic acid and of an active metabolite into brain and liver: possible pharmacological and toxicological consequences.
Löscher W; Nau H
Arch Int Pharmacodyn Ther; 1984 Aug; 270(2):192-202. PubMed ID: 6435554
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid and active unsaturated metabolite (2-en): transfer to mouse liver following human therapeutic doses.
Nau H; Loscher W
Biopharm Drug Dispos; 1985; 6(1):1-8. PubMed ID: 3921077
[TBL] [Abstract][Full Text] [Related]
4. Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment.
Löscher W; Nau H
J Pharmacol Exp Ther; 1983 Sep; 226(3):845-54. PubMed ID: 6411902
[TBL] [Abstract][Full Text] [Related]
5. Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse.
Nau H
Teratology; 1986 Feb; 33(1):21-7. PubMed ID: 3090732
[TBL] [Abstract][Full Text] [Related]
6. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA
Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993
[TBL] [Abstract][Full Text] [Related]
7. A new method for kinetic studies of drug interactions in experimental animals during steady state. Controlled-rate application of valproic acid, phenobarbital and their combinations via implanted osmotic minipumps in the mouse.
Kuhnz W; Zierer R; Nau H
Arzneimittelforschung; 1983; 33(11):1579-82. PubMed ID: 6419746
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture.
Lewandowski C; Klug S; Nau H; Neubert D
Arch Toxicol; 1986 Apr; 58(4):239-42. PubMed ID: 3087328
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the pharmacological and biochemical profiles of valproic acid (VPA) and its cerebral metabolite (2-en-VPA) after oral administration in mice.
Keane PE; Simiand J; Morre M
Methods Find Exp Clin Pharmacol; 1985 Feb; 7(2):83-6. PubMed ID: 2859407
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid: metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice.
Löscher W; Nau H
Arch Int Pharmacodyn Ther; 1982 May; 257(1):20-31. PubMed ID: 6810778
[TBL] [Abstract][Full Text] [Related]
11. Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid.
Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Lockard JS; Thummel KE; Baillie TA
Drug Metab Dispos; 1986; 14(4):443-53. PubMed ID: 2873992
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse.
Nau H; Löscher W
J Pharmacol Exp Ther; 1982 Mar; 220(3):654-9. PubMed ID: 6801254
[TBL] [Abstract][Full Text] [Related]
13. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates.
Rettenmeier AW; Prickett KS; Gordon WP; Bjorge SM; Chang SL; Levy RH; Baillie TA
Drug Metab Dispos; 1985; 13(1):81-96. PubMed ID: 2858383
[TBL] [Abstract][Full Text] [Related]
14. Accumulation and washout kinetics of valproic acid and its active metabolites.
Pollack GM; McHugh WB; Gengo FM; Ermer JC; Shen DD
J Clin Pharmacol; 1986; 26(8):668-76. PubMed ID: 3098806
[TBL] [Abstract][Full Text] [Related]
15. The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid.
Kondo T; Otani K; Hirano T; Kaneko S; Fukushima Y
Br J Clin Pharmacol; 1990 Jan; 29(1):116-9. PubMed ID: 2105099
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy.
Löscher W; Nau H; Marescaux C; Vergnes M
Eur J Pharmacol; 1984 Mar; 99(2-3):211-8. PubMed ID: 6428923
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid.
Hauck RS; Nau H
Toxicol Lett; 1989 Oct; 49(1):41-8. PubMed ID: 2510370
[TBL] [Abstract][Full Text] [Related]
18. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid.
Kassahun K; Abbott F
Drug Metab Dispos; 1993; 21(6):1098-106. PubMed ID: 7905390
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid teratogenicity in mice after various administration and phenobarbital-pretreatment regimens: the parent drug and not one of the metabolites assayed is implicated as teratogen.
Nau H
Fundam Appl Toxicol; 1986 May; 6(4):662-8. PubMed ID: 3086173
[TBL] [Abstract][Full Text] [Related]
20. Enantiotopic differentiation during the biotransformation of valproic acid to the hepatotoxic olefin 2-n-propyl-4-pentenoic acid.
Porubek DJ; Barnes H; Meier GP; Theodore LJ; Baillie TA
Chem Res Toxicol; 1989; 2(1):35-40. PubMed ID: 2519229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
